Barclays’s Terns Pharmaceuticals TERN Stock Holding History

Barclays’s Portfolio TERN Stock Details TERN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-100	Closed	-$5.27K	–	5628
2026 Q1	$5.27K	Buy	+100	New	+$4.11K	﹤0.01%	4768
2024 Q4	–	Sell	-34,400	Closed	-$287K	–	5472
2024 Q3	$287K	Buy	+34,400	New	+$283K	﹤0.01%	4113

Other funds holding TERN

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Barclays's TERN Position: Q2 2026 in Review

Barclays sold out of Terns Pharmaceuticals (TERN) in Q2 2026, closing a stake of 669,601 shares — an estimated $35.3M sold.

Barclays first reported a position in TERN in Q1 2022 and held it in 17 quarters. The position peaked at $35.3M in Q1 2026. 1 fund tracked by Wall St. Rank holds TERN as of Q2 2026.

Barclays reported no remaining Terns Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Barclays sold 669,601 Terns Pharmaceuticals shares in Q2 2026, an estimated $35.3M.
Barclays first reported a position in Terns Pharmaceuticals in Q1 2022 and held it in 17 quarters.
Barclays's Terns Pharmaceuticals position peaked at $35.3M in Q1 2026.
1 fund tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.